08h00 – 08h10

Abertura
Palestrante: Dr. Artur Katz

08h10 - 08h30

Trabalhos selecionados – Parte 1
Palestrante: Dra. Marina Sahade

• - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
• - Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
• Abstract 505: Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutatio-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
• - Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
• - A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.

08h30 - 08h50

Trabalhos selecionados – Parte 2
Palestrante: Dra. Tatiana Strava

• - Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).
• - LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).
• - Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
• - Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.

08h50 - 09h10

Resultados em perspectiva
Palestrante: Dr. Carlos dos Anjos

09h10 - 09h20

Discussão e Q&A – Mama
Moderador: Dra. Andrea Shimada
Debatedores: Dra. Marina Sahade, Dra. Tatiana Strava e Dr. Carlos dos Anjos

09h20 - 09h40

Trabalhos selecionados
Palestrante: Dr. Gustavo Duarte

• - Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis
• - Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).
• - Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600–mutant pediatric low-grade glioma (pLGG).
• - Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.
• - Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma

09h40 - 10h00

Resultados em perspectiva
Palestrante: Dr. David Muniz

10h00 - 10h10

Discussão e Q&A – Neuro
Debatedor: Dr. Gustavo Duarte e Dr. David Muniz

11h00 - 11h20

Trabalhos selecionados – Parte 1
Palestrante: Dr. Daniel Girardi

• - EVEREST: EVErolimus for Renal cancer Ensuing Surgical Therapy, a phase III study (SWOG S0931, NCT01120249)
• - Association between depth of response and clinical outcomes: exploratory analysis in patients with previously untreated advanced renal cell carcinoma in CheckMate 9ER
• - QUILT 3032: Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-Unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)
• - Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.

11h20 - 11h40

Trabalhos selecionados – Parte 2
Palestrante: Dr. Igor Morbeck

• - ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival after median follow-up of 3 years (TheraP ANZUP 1603)
• - [⁶⁸Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [¹⁷⁷Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
• - Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
• - C-16-168: BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.

11h40 - 12h00

Resultados em perspectiva
Palestrante: Dr. Denis Jardim

12h00 - 12h10

Discussão e Q&A – GU
Moderador: Dr. David Muniz
Debatedores: Dr. Daniel Girardi, Dr. Igor Morbeck e Dr. Denis Jardim

13h00 - 13h20

Trabalhos selecionados – Parte 1
Palestrante: Dra. Fernanda Capareli

• - Panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type metastatic colorectal cancer: results from the phase 3 PARADIGM trial.
• - PD-1 blockade as curative-intent therapy in mismatch repair deficient locally advanced rectal cancer.
• - Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial.

13h20 - 13h40

Trabalhos selecionados – Parte 2
Palestrante: Dr. Tulio Pfiffer

• - Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
• - Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2fusions/rearrangements.
• - How Should We Prioritize Targeted Therapy in Cholangiocarcinoma?
• - Surgical and pathological outcome in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
• - Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

13h40 - 14h00

Resultados em perspectiva
Palestrante: Dr. Jorge Sabbaga

14h00 - 14h10

Discussão e Q&A– GI
Moderador: Dr. Tiago Biachi
Debatedores: Dra. Fernanda Capareli, Dr. Tulio Pfiffer e Dr. Jorge Sabbaga

14h10 - 14h30

Trabalhos selecionados – Parte 1
Palestrante: Dr. Rodrigo Saddi

• - Abstract LBA6003 - Results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.
• - Abstract 6000 - Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.
• - Abstract 6008 - A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC).

14h30 - 14h50

Trabalhos selecionados – Parte 2
Palestrante: Dr. Guilherme Harada

• - Abstract 9000 - Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
• - Abstract 9001 - Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
• - Abstract 9002 - KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
• - Abstract LBA 9009 - Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.
• - Abstract 9006 - Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.

14h50 - 15h10

Resultados em perspectiva
Palestrante: Dr. Marcelo Cruz

15h10 - 15h20

Discussão e Q&A – Pulmão
Moderador: Dr. Rodrigo Medeiros
Debatedores: Dr. Rodrigo Saddi, Dr. Guilherme Harada e Dr. Marcelo Cruz

15h20 - 15h40

Intervalo

15h40 - 16h00

Trabalhos selecionados – Parte 1
Palestrante: Dr. Allan Andresson

• - Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
• - Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.
• - NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.

16h00 - 16h20

Trabalhos selecionados – Parte 2
Palestrante: Dra. Tatiana Strava

• - Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.
• - Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.
• - Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.

16h20 - 16h40

Resultados em perspectiva
Palestrante: Dr. Rodrigo Munhoz

16h40 - 16h50

Discussão e Q&A – Melanoma/Sarcoma
Moderador: Dr. David Muniz
Debatedores: Dr. Allan Andresson, Dr. Tatiana Strava e Dr. Rodrigo Munhoz

16h50 - 17h10

Trabalhos selecionados – Parte 1
Palestrante: Dr. Carlos dos Anjos

• - Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
• - Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.
• - An open-label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer.

17h10 - 17h30

Trabalhos selecionados – Parte 2
Palestrante: Dr. Rudinei Linck

• - Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.
• - ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.
• - Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

17h30 - 17h50

Resultados em perspectiva
Palestrante: Dra. Daniele Assad

17h50 - 18h00

Discussão e Q&A – Tumores Ginecológicos
Moderadora: Dra. Daniela de Freitas
Debatedores: : Dr. Carlos dos Anjos, Dr. Rudinei Linck e Dra. Daniele Assad